Preclinical models have demonstrated that chemotherapy drugs including cisplatin promote the activation of the NF-κB pathway, which is responsible in part for drug resistance in carcinoma cell lines (Chuang et al., 2002; Yeh et al., 2002; Yeh et al., 2003; Li et al., 2005). Here, NFKB1 is linked to carcinoma.